LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the malignant glioma market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat malignant glioma.
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Malignant glioma: Market overview
Malignant glioma comprises a group of tumors arising from the glial cells in the brain or spinal cord. They are broadly dicided into astrocytomas and oilgodendrogliomas. Astrocytomas are graded from I to IV. The most common subtype of primary brain tumors is malignant glioma, which is very aggressive, highly invasive, and neurologically destructive tumor.
According to a senior analyst at Technavio for research on infectious and rare diseases, “The symptoms of malignant glioma are a headache, nausea or vomiting, confusion or a decline in brain function, memory loss, personality changes, and irritability.”
Malignant glioma segmentation
This market research report segments the malignant glioma market based on therapies employed that includes combination therapy, monotherapy, and unknown, RoA (oral, IV, intratumoral, IV and oral, parental and oral, subcutaneous, IM and EP, intradermal injection, and unknown), therapeutic modalities (small molecule, monoclonal antibody, vaccine, oncolytic virus and monoclonal antibody, gene therapy, recombinant protein, and unknown), targets for drugs under development (PD-1, EGFR, IL, T-cell, cell cycle, IDO, others, and unkown), drugs under development (pre-clinical, phase I, phase I/II, phase II, and phase III), and recruitment status (recruiting, active not recruiting, completed, not yet recruiting, and unknown). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Recruitment volume
- Type of players
- Company Overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.